The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study
Objective: This study was designed to evaluate the effects of 3 mg drospirenone/30 μg ethinyl estradiol (OC) alone or combined with 1700 mg metformin on metabolic risk factors. Materials and methods: In this randomized, prospective, controlled study, 87 non-obese (18–30 BMI) women of reproductive ag...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-06-01
|
| Series: | Taiwanese Journal of Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1028455918300810 |
| _version_ | 1818231406762917888 |
|---|---|
| author | Serkan Bodur Ozgur Dundar Mine Kanat-Pektas Mehmet Ferdi Kinci Levent Tutuncu |
| author_facet | Serkan Bodur Ozgur Dundar Mine Kanat-Pektas Mehmet Ferdi Kinci Levent Tutuncu |
| author_sort | Serkan Bodur |
| collection | DOAJ |
| description | Objective: This study was designed to evaluate the effects of 3 mg drospirenone/30 μg ethinyl estradiol (OC) alone or combined with 1700 mg metformin on metabolic risk factors.
Materials and methods: In this randomized, prospective, controlled study, 87 non-obese (18–30 BMI) women of reproductive age (18–39) with polycystic ovary syndrome (PCOS) were assigned to control (n = 17), OC (n = 21), combination (n = 20) and metformin (n = 29) therapy groups.
Results: Adiponectin levels changed −28.27%, −20.37% and 35.78% after OC, combination and metformin therapies, respectively. High sensitive C-reactive protein levels (hsCRP) changed with OC, combination and metformin therapies by 102.32%, 3.2% and −7.14%, respectively. Plasminogen activator inhibitor-1 levels decreased 41.34% in the metformin group. Apolipoprotein-B levels changed in a manner similar to changes in hsCRP levels. The homeostatic model insulin resistance index changed significantly between the groups following treatment (p = 0.001).
Conclusion: Six cycles of treatments with OC alone may cause metabolic variables to deteriorate in non-obese women with PCOS. The addition of metformin to OC may ameliorate some aspects of this effect. |
| first_indexed | 2024-12-12T10:49:53Z |
| format | Article |
| id | doaj.art-911128fb70d74be9a7ce9bd726808d78 |
| institution | Directory Open Access Journal |
| issn | 1028-4559 |
| language | English |
| last_indexed | 2024-12-12T10:49:53Z |
| publishDate | 2018-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Taiwanese Journal of Obstetrics & Gynecology |
| spelling | doaj.art-911128fb70d74be9a7ce9bd726808d782022-12-22T00:26:48ZengElsevierTaiwanese Journal of Obstetrics & Gynecology1028-45592018-06-0157341141610.1016/j.tjog.2018.04.015The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled studySerkan Bodur0Ozgur Dundar1Mine Kanat-Pektas2Mehmet Ferdi Kinci3Levent Tutuncu4Gulhane Training and Research Hospital, Department of Obstetrics and Gynecology, Ankara, TurkeyHaydarpasa Sultan Abdülhamit Training and Research Hospital, Department of Obstetrics and Gynecology, Istanbul, TurkeyAfyon Kocatepe University Medical Faculty Hospital, Department of Obstetrics and Gynecology, Afyon, TurkeyGulhane Training and Research Hospital, Department of Obstetrics and Gynecology, Ankara, TurkeyHaydarpasa Sultan Abdülhamit Training and Research Hospital, Department of Obstetrics and Gynecology, Istanbul, TurkeyObjective: This study was designed to evaluate the effects of 3 mg drospirenone/30 μg ethinyl estradiol (OC) alone or combined with 1700 mg metformin on metabolic risk factors. Materials and methods: In this randomized, prospective, controlled study, 87 non-obese (18–30 BMI) women of reproductive age (18–39) with polycystic ovary syndrome (PCOS) were assigned to control (n = 17), OC (n = 21), combination (n = 20) and metformin (n = 29) therapy groups. Results: Adiponectin levels changed −28.27%, −20.37% and 35.78% after OC, combination and metformin therapies, respectively. High sensitive C-reactive protein levels (hsCRP) changed with OC, combination and metformin therapies by 102.32%, 3.2% and −7.14%, respectively. Plasminogen activator inhibitor-1 levels decreased 41.34% in the metformin group. Apolipoprotein-B levels changed in a manner similar to changes in hsCRP levels. The homeostatic model insulin resistance index changed significantly between the groups following treatment (p = 0.001). Conclusion: Six cycles of treatments with OC alone may cause metabolic variables to deteriorate in non-obese women with PCOS. The addition of metformin to OC may ameliorate some aspects of this effect.http://www.sciencedirect.com/science/article/pii/S1028455918300810Polycystic ovary syndromeOral contraceptivesDrospirenoneMetforminMetabolic syndrome |
| spellingShingle | Serkan Bodur Ozgur Dundar Mine Kanat-Pektas Mehmet Ferdi Kinci Levent Tutuncu The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study Taiwanese Journal of Obstetrics & Gynecology Polycystic ovary syndrome Oral contraceptives Drospirenone Metformin Metabolic syndrome |
| title | The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study |
| title_full | The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study |
| title_fullStr | The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study |
| title_full_unstemmed | The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study |
| title_short | The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study |
| title_sort | effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome a randomized controlled study |
| topic | Polycystic ovary syndrome Oral contraceptives Drospirenone Metformin Metabolic syndrome |
| url | http://www.sciencedirect.com/science/article/pii/S1028455918300810 |
| work_keys_str_mv | AT serkanbodur theeffectsofdifferenttherapeuticmodalitiesoncardiovascularriskfactorsinwomenwithpolycystıcovarysyndromearandomızedcontrolledstudy AT ozgurdundar theeffectsofdifferenttherapeuticmodalitiesoncardiovascularriskfactorsinwomenwithpolycystıcovarysyndromearandomızedcontrolledstudy AT minekanatpektas theeffectsofdifferenttherapeuticmodalitiesoncardiovascularriskfactorsinwomenwithpolycystıcovarysyndromearandomızedcontrolledstudy AT mehmetferdikinci theeffectsofdifferenttherapeuticmodalitiesoncardiovascularriskfactorsinwomenwithpolycystıcovarysyndromearandomızedcontrolledstudy AT leventtutuncu theeffectsofdifferenttherapeuticmodalitiesoncardiovascularriskfactorsinwomenwithpolycystıcovarysyndromearandomızedcontrolledstudy AT serkanbodur effectsofdifferenttherapeuticmodalitiesoncardiovascularriskfactorsinwomenwithpolycystıcovarysyndromearandomızedcontrolledstudy AT ozgurdundar effectsofdifferenttherapeuticmodalitiesoncardiovascularriskfactorsinwomenwithpolycystıcovarysyndromearandomızedcontrolledstudy AT minekanatpektas effectsofdifferenttherapeuticmodalitiesoncardiovascularriskfactorsinwomenwithpolycystıcovarysyndromearandomızedcontrolledstudy AT mehmetferdikinci effectsofdifferenttherapeuticmodalitiesoncardiovascularriskfactorsinwomenwithpolycystıcovarysyndromearandomızedcontrolledstudy AT leventtutuncu effectsofdifferenttherapeuticmodalitiesoncardiovascularriskfactorsinwomenwithpolycystıcovarysyndromearandomızedcontrolledstudy |